biologic

Nplate

romiplostim

Loss of exclusivityJuly 2031projected — 12-year biologic exclusivity estimate
CompanyAmgenView the full company profile on CliffBio

Drug detail

Brand nameNplate
Active ingredientromiplostim
Strength125MCG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalJuly 2019
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found